Biogen
(NASDAQ:BIIB)
$301.85
At close: Dec 1(Delayed 15-Minutes)
Get Real Time Here
$301.85
PreMarket: 4:57PM EDT
Day Range- - -52 Wk Range187.16 - 311.88Open / Close- / -Float / Outstanding127.3M / 144M
Vol / Avg.- / 1.7MMkt Cap43.5BP/E15.4250d Avg. Price273.68
Div / Yield-Payout Ratio-Total Float127.3MEPS7.86

Biogen Stock (NASDAQ:BIIB), Quotes and News Summary

Biogen Stock (NASDAQ: BIIB) stock price, news, charts, stock research, profile.

Loading...
Day Range- - -52 Wk Range187.16 - 311.88Open / Close- / -Float / Outstanding127.3M / 144M
Vol / Avg.- / 1.7MMkt Cap43.5BP/E15.4250d Avg. Price273.68
Div / Yield-Payout Ratio-Total Float127.3MEPS7.86
Seeking Alpha - 1 day ago
TalkMarkets - 3 days ago
StockNews - Nov 23, 2022, 10:08AM
StockNews - Nov 17, 2022, 6:01AM
TipRanks - Nov 16, 2022, 8:45PM
Sector: Health Care.Industry: Biotechnology
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-02-02
REV
Q3 2022Est.ActualSurprise
EPS4.1604.770 0.6100
REV2.470B2.509B38.500M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Biogen (BIIB) stock?

A

You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Biogen (BIIB) stock?

A

The latest price target for Biogen (NASDAQ: BIIB) was reported by Atlantic Equities on Thursday, December 1, 2022. The analyst firm set a price target for 295.00 expecting BIIB to fall to within 12 months (a possible -2.27% downside). 71 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Biogen (BIIB)?

A

The stock price for Biogen (NASDAQ: BIIB) is $301.85 last updated December 1, 2022, 9:00 PM UTC.

Q

Does Biogen (BIIB) pay a dividend?

A

There are no upcoming dividends for Biogen.

Q

When is Biogen (NASDAQ:BIIB) reporting earnings?

A

Biogen’s Q4 earnings are confirmed for Thursday, February 2, 2023.

Q

Is Biogen (BIIB) going to split?

A

There is no upcoming split for Biogen.

Q

What sector and industry does Biogen (BIIB) operate in?

A

Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.